Christine Ring Sells 3,290 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 3,290 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $25.00, for a total value of $82,250.00. Following the sale, the insider now owns 24,592 shares in the company, valued at $614,800. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Christine Ring also recently made the following trade(s):

• On Tuesday, October 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The stock was sold at an average price of $22.23, for a total value of $128,044.80.
• On Tuesday, September 3rd, Christine Ring sold 9,050 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.94, for a total value of $225,707.00.
• On Monday, August 26th, Christine Ring sold 9,870 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.01, for a total transaction of $246,848.70.
• On Thursday, August 1st, Christine Ring sold 5,760 shares of Nurix Therapeutics stock. The shares were sold at an average price of $21.43, for a total value of $123,436.80.

Nurix Therapeutics Trading Up 3.8 %

Shares of NRIX stock opened at $25.81 on Thursday. The firm has a fifty day moving average price of $23.55 and a 200 day moving average price of $19.47. The company has a market cap of $1.27 billion, a P/E ratio of -8.84 and a beta of 2.22. Nurix Therapeutics, Inc. has a 12 month low of $4.22 and a 12 month high of $26.31.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. On average, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.95 EPS for the current year.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its holdings in shares of Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after buying an additional 3,424 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Nurix Therapeutics in the first quarter valued at about $123,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Nurix Therapeutics by 67.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after buying an additional 3,793 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Nurix Therapeutics by 9.1% in the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after buying an additional 998 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new stake in shares of Nurix Therapeutics in the second quarter valued at about $201,000.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Barclays boosted their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. Royal Bank of Canada cut their target price on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research report on Monday. JPMorgan Chase & Co. upped their price objective on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Finally, Jefferies Financial Group initiated coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 price objective on the stock. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $28.71.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.